Expects to launch and complete a Phase 1 trial in Q4 2023
A New Jersey-based %Biotech company is turning heads Tuesday morning after the company announced the signing an exclusive option agreement with %DanaFarberCancerInstitute to license technology targeting...
BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company...
Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors...
Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors...
Recent milestones include FDA Orphan Drug Designations for HSB-1216 and HSB-888 World-class scientific advisory team and growing and distinguished patent...
Developed in partnership with J.P. Morgan and Johnson & Johnson Innovation, the Conference will bring together more than 500 life sciences...
HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomasHSB-1216 was recently granted Orphan Drug...
-Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease- -Evidence implicates...
Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15 million Initial Public Offering on January 14, 2022 R&D Day to Review Novel...